Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2019 19:32 ET | Source: resTORbio, Inc.

resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
March 18, 2019 16:17 ET | Source: resTORbio, Inc.

resTORbio, Inc. Announces Proposed Public Offering of Common Stock

BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
March 18, 2019 16:01 ET | Source: resTORbio, Inc.

resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results

Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in combination with sirolimus in...
March 18, 2019 07:12 ET | Source: resTORbio, Inc.

resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101

Phase 3 program on track to start enrolling patients in the second quarter of 2019 Data from two Phase 2 clinical trials enrolling more than 900 patients support the design of the Phase 3 program ...
February 21, 2019 08:00 ET | Source: resTORbio, Inc.

resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent...
February 06, 2019 08:30 ET | Source: resTORbio, Inc.

resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry

BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or...
January 31, 2019 16:30 ET | Source: resTORbio, Inc.

resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease

BOSTON, Jan. 31, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or...
December 19, 2018 08:00 ET | Source: resTORbio, Inc.

resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences

BOSTON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
November 13, 2018 08:00 ET | Source: resTORbio, Inc.

resTORbio Reports Third Quarter 2018 Financial Results

Additional positive data from Phase 2b trial further support RTB101’s potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients Initiation of pivotal...
November 08, 2018 07:12 ET | Source: resTORbio, Inc.

resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting

BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right